Andrea M. Gross, MD
- Director, Neurofibromatosis Program, Division of Oncology
- Associate Professor, UC Department of Pediatrics
- andrea.gross@cchmc.org
- Board Certified
About
Biography
I am an associate professor of pediatrics and the director of the Neurofibromatosis Program within the Division of Oncology. My clinical focus includes neurofibromatosis, plexiform neurofibromas, malignant peripheral nerve sheath tumors and pediatric solid tumors. My research interests center on developmental therapeutics, functional outcome assessments and preventing neurofibromatosis tumor-related morbidity and mortality.
I received my medical degree from the University of Connecticut School of Medicine. I completed my pediatric residency at Cincinnati Children’s, where I also served as chief resident, followed by a fellowship in pediatric hematology/oncology at Children’s National Hospital in Washington, D.C.
BS: University of Connecticut, 2006
MD: University of Connecticut School of Medicine, 2010
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 2013
Chief Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 2014
Fellowship: Pediatric Hematology / Oncology, Children's National Hospital, 2017
Certifications: General Pediatrics, American Board of Pediatrics, 2013; Pediatric Hematology / Oncology, American Board of Pediatrics, 2019
Interests
Neurofibromatosis; plexiform neurofibromas; malignant peripheral nerve sheath tumors; pediatric solid tumors; clinical research
Services and Specialties
Interests
Developmental therapeutics; functional outcome assessments; prevention of tumor-related morbidity and mortality
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nature Medicine. 2025; 31(1):105-115.
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment. Genetics in Medicine. 2026; 28(6):102561.
Wide Ranging Neurobehavioral Phenotype in Individuals With Costello Syndrome. American Journal of Medical Genetics, Part A. 2026; 200(5):1138-1144.
MEK inhibitor-induced dropped head syndrome in pediatrics. Neuro-Oncology Pediatrics. 2026; 2(2):wuag024.
Evolution of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Opportunities for Prevention and Therapeutic Strategies. Annual Review of Cancer Biology. 2026; 10(1):223-241.
Abstract 2548: Circulating proteomic signatures for subtyping NF1 associated peripheral nerve sheath tumors. Cancer Research. 2026; 86(7_Supplement):2548-2548.
Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations. Neuro-Oncology. 2026; 28(4):847-863.
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST). Clinical Cancer Research. 2026; 32(6):1068-1077.
Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception. Journal of the National Cancer Institute. 2026.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey